Can we predict the severe course of COVID-19 – a systematic review and meta-analysis of indicators of clinical outcome?

Stephan Katzenschlager^{*,1}, Alexandra J. Zimmer^{*,2}, Claudius Gottschalk³, Juergen Grafeneder⁴, Alexander Seitel⁵, Lena Maier-Hein⁵, Andrea Benedetti², Jan Larmann¹, Markus A. Weigand¹, Sean McGrath^{+,6}, Claudia M. Denking^{+,3,7}

1) Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany

2) Departments of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada

3) Division of Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.

4) Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

5) Division of Computer Assisted Medical Interventions, German Cancer Research Center (DKFZ), Heidelberg, Germany

6) Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, USA

7) German Center for Infection Research (DZIF), partner site Heidelberg

* contributed equally

+ contributed equally

Keywords: Covid-19; outcome prediction; meta-analysis; risk factors; mortality

Running Title: Meta-analysis: Risk factors of COVID-19

Corresponding author:

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Claudia M. Denking

Division of Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany

Claudia.Denkinger@uni-heidelberg.de

+49 6221 56 36637

Alternate corresponding author:

Stephan Katzenschlager

Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany

stephan.katzenschlager@med.uni-heidelberg.de

+49 6221 56 39683

Summary: In this systematic review we meta-analyzed 88 articles for risk factors of ICU admission and mortality in COVID-19. We found age, cerebrovascular disease, CRP, LDH and cTnI are the most important risk-factors for ICU admission or mortality.

Abstract

Background: COVID-19 has been reported in over 40million people globally with variable clinical outcomes. In this systematic review and meta-analysis, we assessed demographic, laboratory and clinical indicators as predictors for severe courses of COVID-19.

Methods: We systematically searched multiple databases (PubMed, Web of Science Core Collection, MedRvix and bioRvix) for publications from December 2019 to May 31st 2020. Random-effects meta-analyses were used to calculate pooled odds ratios and differences of medians between (1) patients admitted to ICU versus non-ICU patients and (2) patients who died versus those who survived. We adapted an existing Cochrane risk-of-bias assessment tool for outcome studies.

Results: Of 6,702 unique citations, we included 88 articles with 69,762 patients. There was concern for bias across all articles included. Age was strongly associated with mortality with a difference of medians (DoM) of 13.15 years (95% confidence interval (CI) 11.37 to 14.94) between those who died and those who survived. We found a clinically relevant difference between non-survivors and survivors for C-reactive protein (CRP; DoM 69.10, CI 50.43 to 87.77), lactate dehydrogenase (LDH; DoM 189.49, CI 155.00 to 223.98), cardiac troponin I (cTnI; DoM 21.88, CI 9.78 to 33.99) and D-Dimer (DoM 1.29mg/L, CI 0.9 - 1.69). Furthermore, cerebrovascular disease was the co-morbidity most strongly associated with mortality (Odds Ratio 3.45, CI 2.42 to 4.91) and ICU admission (Odds Ratio 5.88, CI 2.35 to 14.73).

Discussion: This comprehensive meta-analysis found age, cerebrovascular disease, CRP, LDH and cTnI to be the most important risk-factors in predicting severe COVID-19 outcomes and will inform decision analytical tools to support clinical decision-making.

Introduction

Coronavirus disease (COVID-19) was declared a pandemic by the World Health Organization (WHO) on March 11th, 2020 [1]. As of October 31st approximately 46 million people were infected with this virus [2]. The outcomes of COVID-19 vary from completely asymptomatic to hospitalization, ICU admission and death [3, 4].

Several studies aimed to identify possible risk factors for a severe outcome. Studies investigated demographic risk factors and found advanced age to be the strongest predictor of a severe course [5-7]. However, age alone does not explain the variability in the severity of disease with sufficient granularity [8]. Symptoms on presentation associated with severe disease include dyspnea, fever, cough, and fatigue [6, 9, 10]. Several co-morbidities have been identified as risk factors, including cardiovascular disease, obesity, chronic respiratory disease, diabetes, cerebrovascular disease, chronic renal failure and cancer [7, 11-16]. The effect of other co-morbidities on disease outcome remain less clear: e.g. hypertension being associated with a decreased risk [7, 17] for death in some and an increased risk [18] in other publications. Similarly, data on past and current smoking are inconsistent in respect of the association with disease severity [19-23]. Biomarkers predicting severe disease include different markers of inflammation and acute phase reaction (e.g. CRP, procalcitonin (PCT), white blood cells (WBC), lymphopenia, interleukin 6 (IL-6)) [24, 25]. Increased D-Dimer levels, as a marker for coagulation and thrombosis, were found to be elevated in non-survivors, whereas other coagulation markers failed to show statistical and clinical difference [13, 26-28]. Markers indicating cardiac damage, such as cardiac troponin I or T and N terminal pro B type natriuretic peptide (NT-proBNP) were also associated with severe disease and mortality [29].

This systematic review aims, to our knowledge for the first time, to comprehensively evaluate demographic, clinical and laboratory indicators for their association with severe COVID-19 and death.

Methods

This trial was registered at PROSPERO on April 4th, 2020 (Registration number: CRD42020177154). The PRISMA checklist is provided in the supplementary file S2.

Eligibility criteria

Studies eligible for inclusion provided data on demographic, clinical and/or laboratory risk factors for the following outcomes: hospitalization, intubation, ICU admission, and/or death. Laboratory values and vital parameters taken at hospital admission were considered. Cross-sectional studies, cohort studies, randomized and non-randomized controlled trials were included. No specific restrictions were placed in terms of demographic and clinical characteristics of the population being studied. The search was conducted on July 29th, the search date was set from December 1st 2019 to May 31st 2020.

Search strategy

Medline [PubMed] and Web of Science Core Collection as well as preprint databases (bioRxiv and medRxiv) were searched. The exact search terms were developed with an experienced medical librarian (GG) using combinations of subject headings (when applicable) and text-words for the concepts without language restrictions. The full search strategy used for PubMed is presented in the supplementary file S1. The results of the search term were imported into the bibliography manager Zotero (Version 5.0.92) for further processing.

Study screening and data extraction

Study selection was done by three authors (SK, CG and JG) initially in parallel for five randomly selected papers and after alignment in the selection was guaranteed, it was done independently by each of the reviewers. Article title and abstracts were screened for eligibility, followed by a full-text review for those eligible.

A structured electronic data extraction form was developed (AS, LMH, SO, LAS and BP), piloted on five randomly selected papers and then used to extract information from included studies. Six reviewers (SK, CG, SS, SaK, MG and AM) performed data extraction in duplicate for the first five randomly selected papers to ensure alignment and then independently, with concerns being discussed jointly. For continuous indicators we extracted means and standard deviation as well as medians, first quartiles and third quartiles if available. The comprehensive list of data items that were collected is presented in the supplementary file S12.

Throughout screening and extraction, disagreements were discussed until consensus was reached, and a senior author (CMD) was consulted when necessary.

Given the concern for reporting of the same patients in different publications [30] leading to a bias in the data, we excluded papers which included patients from the same hospital with an overlapping inclusion date. Furthermore, we excluded data from 23 articles (peer-reviewed and preprint), because the reported laboratory values with the reported units were obviously incorrect (Supplementary file S3), unless we were able to clarify the issue with the authors of the respective paper directly.

Assessment of study quality

To analyze risk of bias in individual studies, we evaluated the studies using an approach adapted from an existing Cochrane tool by Higgins et al. [31] for systematic reviews that assessed indicators of outcomes. Specifically, we analyzed three areas: 1) case definition and severity definition; 2) patient data availability and exclusions and; 3) selection bias and applicability. We rated the risk of bias in low, intermediate and high risks of bias.

Statistical analysis

We grouped indicators into binary and continuous indicators across five categories: (1) demographics, (2) symptoms, (3) co-morbidities, (4) laboratory and (5) clinical course/treatment. We analyzed all available indicators between (1) hospitalized and non-hospitalized patients, (2) ICU-admitted patients and non-ICU admitted patients, (3) intubated and non-intubated patients, and (4) patients who died and patients who survived. Most data were available for ICU admission and death. Thus, we focus on these comparison groups in the main paper and present data on hospitalization and intubation in the supplement.

Meta-analyses were only performed when there were at least 4 primary studies reporting adequate summary data. As the continuous indicators were often skewed and were summarized by medians in most primary studies, we meta-analyzed the difference of medians across groups for continuous indicators. Specifically, we pooled the difference of medians in a random effects meta-analysis using the Quantile Estimation (QE) approach proposed by McGrath et al. [32]. In secondary analyses, median value of indicators in each comparison group were pooled using the same approach.

The QE approach estimates the variance of the difference of medians in studies that report the sample median and first and third quartiles of the outcome. When studies report sample means and standard deviations of the outcome, this approach estimates the difference of medians and its variance. Then, the standard inverse-variance approach is applied to obtain a pooled estimate of the population (difference of) medians.

For binary indicators, the pooled odds ratios (OR) and associated 95% confidence intervals (CI) were estimated in a random effects meta-analysis. For both binary and continuous indicators, the restricted maximum likelihood (REML) approach was used to estimate between-study heterogeneity. When REML failed to converge, we used the DerSimonian and Laird (DL) estimator for continuous indicators. We considered findings as statistically significant if $p < 0.05$.

For all analyses, between-study heterogeneity was assessed by the I^2 statistic. The presence of publication bias was visually assessed in funnel plots. Analyses were performed in R (version 4.0.2) with package ‘metamedian’ [33] and in Stata (Version 16.1). The code is publicly available on GitHub (<https://github.com/stmcg/covid-ma>).

Results

The search resulted in 6,702 articles, of which 3,733 were excluded because they did not present primary data (e.g. guidelines, recommendations, letter to the editors or correspondences, study protocols, modeling), 792 were case reports, 465 focused on patients younger than 18 years and 381 were systematic reviews. In total, 88 articles were included (Figure 1). The majority of studies (52) were conducted in China, 21 in Europe, 12 in the USA, two in Iran, one in South Korea. Most studies were retrospective cohorts (n=84) and four had a prospective study design. All studies were in English. Data on mortality were reported in 64 studies, data on ICU admission were available in 26 studies (two studies reported both and patients were counted twice). In total, data from 69,762 patients were meta-analyzed, of whom 5,311 died and 57,321 survived and 2,112 provided data on ICU-admission while 5,018 did not require ICU admission.

Study quality

The findings on study quality can be found in Figure 2. When considering the case and severity definition of COVID-19 almost 50% of studies were considered low risk of bias, while only 9.1% had a high risk. In contrast, many studies were identified to have high concerns for bias in respect to patient selection and generalizability of findings (36.4% high risk, 9.1% low risk). In more than a third of studies, we had high concern that the full data on patients were not available and inappropriate exclusion might have occurred (35.2%). The full explanation of the risk of bias assessment and the assessment of each paper individually is available in the supplement S4. Overall, high- or intermediate risk of bias for at least one category was found in almost three fourth (73.8%) of studies. No study scored low risk in all three categories.

ICU admission

Figure 3A and Table 1 show the pooled odds ratios (OR) and differences of medians, respectively, for ICU admission for the different indicators in the five categories: demographic, symptoms, comorbidities, laboratory and clinical values [12, 13, 27, 34-55].

Patients requiring ICU admission had a median age of 65 years (CI 62.27 to 66.16). Those not requiring ICU admission were significantly younger with a median age of 59 years (CI 55.93 to 61.86) with a DoM of

4.63 years (CI 1.43 to 7.82) (Table 1). We were not able to perform a subgroup analysis of different age groups as data provided by primary studies was insufficient.

Of the many possible symptoms of COVID-19, we found dyspnea (OR 5.34, CI 2.77 to 10.28) and fatigue (OR 1.63, CI 1.20 to 2.22) to be significantly associated with ICU admission. In terms of co-morbidities, patients admitted to the ICU were more likely to suffer from cerebrovascular disease (OR 5.88, CI 2.35 to 14.73), hypertension (OR 1.62 CI 1.24 to 2.12), diabetes (OR 1.58, CI 1.29 to 1.93) and chronic kidney disease (OR 1.48, CI 1.08 to 2.03). In contrast, cardiovascular diseases (OR 1.50, CI 0.99 to 2.28), chronic obstructive pulmonary disease (COPD) (OR 1.39, CI 0.90 to 2.16), chronic lung disease (OR 1.06, CI 0.89 to 1.25) and smoking (OR 1.00, CI 0.77 to 1.29) were not associated with ICU admission.

Few laboratory values showed differences between patients that required ICU admission and those who did not (Table 1). D-Dimer failed to show a statistically significant difference (DoM 0.3 mg/L, CI -0.2 to 0.81). We found a clinically relevant elevation of CRP and cardiac Troponin I (cTnI) in patients requiring ICU admission, although cTnI failed to be statistically significant (DoM for CRP 56.41 mg/L, CI 39.8 to 73.02 and DoM for cTnI 19.27 pg/mL, CI -4.13 to 42.68). A clinically significant reduction in lymphocytes was also observed (DoM -0.34, CI -0.39 to -0.29). Leukocytes, neutrophils and LDH were also significantly higher in patients admitted to an ICU, but the absolute elevation over those in non-ICU patients were small and of questionable clinical relevance (Table 1).

Patients developing acute kidney failure, as a complication at any stage, had the highest risk for ICU admission (OR 15.69, CI 11.22 to 21.90).

Mortality

Figure 3B and Table 2 show the pooled odds ratios and differences of medians, respectively, for mortality for symptoms, comorbidities, laboratory and clinical values [11, 16, 26, 56-108].

Patients who died had a median age of 71 years (CI 69.3 to 71.61) compared to survivors with a median age of 58 years (CI 55.03 to 59.4) for a DoM of 13.15 years (CI 11.37 to 14.94] (Table 2). Again, dyspnea was the symptom that differentiated markedly between survivors and non-survivors (OR 3.69, CI 2.54 to 5.36). Also, fatigue was more frequently observed in those who died (OR 1.48, CI 1.15 to 1.89).

Patients who died were more likely to suffer from cardiovascular disease (OR 3.93, CI 2.91 to 5.30), cerebrovascular disease (OR 3.45, CI 2.42 to 4.91), chronic lung disease (OR 3.12, CI 2.17 to 4.49), COPD (OR 2.54, CI 1.87 to 3.44; Table 3B) and hypertension (OR 2.49, CI 2.11 to 2.94). Current and former smokers had an increased risk of mortality (OR 1.36, CI 1.10 to 1.67). Patients with chronic kidney disease (CKD) (OR 2.36, CI 1.89 to 2.94), diabetes (OR 2.14, CI 1.82 to 2.52) and cancer (OR 2.08, CI 1.55 to 2.77) also had an increased risk. Co-morbidities not associated with an increased risk of mortality were asthma, liver disease, digestive system disease and immunosuppressive therapy (Table 3B). Clinically relevant elevations outside the normal laboratory range in patients who died compared to those who survived were observed in two markers of inflammation: CRP was elevated by 69.1mg/L (CI 50.43 to 87.77) and IL-6 by 31.19 pg/mL (CI 11.96 to 50.41). Furthermore, clinically significant elevations were observed in cTnI by 21.88pg/mL (CI 9.78 to 33.99) and D-Dimer by 1.29mg/L (CI 0.9 to 1.69), while lymphocytes were significantly lower: $-0.34 \times 10^9/L$ (CI -0.39 to -0.29). Other makers (hemoglobin, leukocytes, neutrophils, platelets, international normalized ratio (INR), Prothrombin, alanine transaminase (ALAT), aspartate transaminase (ASAT), Albumin, LDH, blood urea nitrogen (BUN), Creatinine, PCT, BNP, CK and creatine kinase myocardial band (CK-MB)) were also significantly elevated in those who died, however, the absolute difference compared to those who survived was small and thus likely not clinically relevant. For leukocytes, neutrophils, platelets, prothrombin, ALAT, ASAT, BUN, Creatinine, CK and CK-MB the point estimates even stayed within the normal laboratory range.

As a clinical complication, acute kidney injury showed the highest overall risk ratio for mortality (OR 20.87, CI 9.21 to 47.32), followed by requiring non-invasive ventilation (NIV) (OR 7.38, CI 4.25 to 12.82). Patients who died presented with a median peripheral oxygen saturation (SpO₂) on room air of 89% (CI 87.32 to 90.91) to the hospital, while those who survived had 95% (CI 94.59 to 96.63) (DoM -6.33%, CI -8.14 to -4.52).

Figure 4 shows pooled median estimates along with their normal laboratory ranges for selected number of indicators among patients who died, patients who survived, ICU-admitted patients, and non-ICU admitted patients. Pooled difference of medians estimates for all indicators are available in the supplementary files (S5 for mortality, S6 for ICU admission, S7 for intubation and hospitalization in S8). After removing large outliers in a sensitivity analyses for CRP and D-Dimer, results did not change substantially (results available in the

supplementary file S9). Funnel plots showed no substantial asymmetry suggesting publication bias except for data assessing acute kidney injury (supplementary file S10 for mortality and S11 for ICU admission).

Discussion

In this comprehensive systematic review and meta-analysis, we confirm known markers of severe disease for COVID-19 and shed light on further indicators, whose significance was indeterminate to date.

With respect to co-morbidities, we confirm cardiovascular disease (OR 3.93), chronic lung disease (OR 3.12) and COPD (OR 2.54) as strong risk factors of mortality among COVID-19 patients but not for ICU admission. Only cerebrovascular disease was strongly associated with an increased risk of both ICU admission and death (almost six- and three-fold higher ratio for ICU admission and death, respectively). Overall, the finding that cerebrovascular disease is associated with poor outcomes is in line with the more recent data highlighting the importance of delirium and an overall depressed mental state in severe COVID-19 [109-111]. Our findings confirm chronic kidney disease, diabetes and COPD/chronic lung disease as risk factors, however, associations are less strong than those for cardiovascular or cerebrovascular disease [109]. Evidence from previous studies regarding the risk associated with hypertension has been inconclusive. Our work identifies hypertension as a clear risk factor for ICU admission (OR 1.62, CI 1.24 to 2.12) and death (OR 2.49, CI 2.11 to 2.94) [7, 17, 18]. Similarly, while prior data were inconclusive with respect to the influence of smoking for severe COVID-19 [20-23], our meta-analysis shows the increased risk of mortality among smokers (OR 1.36, CI 1.10 to 1.67). However, our data did not allow for meta-regression to assess whether this effect was independent of the risk associated with chronic lung disease. In line with some recent studies on asthma, we could not find an increased risk for mortality [112] in our meta-analysis (OR 0.88, CI 0.58 to 1.35).

CRP was the only laboratory marker that was associated with a higher risk of ICU admission (DoM 56.41 mg/L) and death (DoM 69.1 mg/L), while D-Dimer elevation was only significantly associated with death (DoM 1.29 mg/L), but not with ICU admission. Although the median elevation of cTnI was clinically relevant

both in those who were admitted to the ICU (DoM 19.27 pg/mL) and those who died (DoM 21.88 pg/mL), only in those who died was the difference statistically significant.

We were able to confirm clinically relevant lymphopenia as a marker. Lymphopenia was a marker that was used early on for triage purposes to predict disease severity [113] and our findings confirm the systematic review results on this topic published by Huang and Pranata [114].

Strengths and limitations of this study

Our study provides a comprehensive review of the data from both pre-print and peer-reviewed sources with a broad geographic distribution and assesses the different categories of risk factors from symptoms, co-morbidities, laboratory values to clinical complications. Correlating the indicators to the two clinical outcomes death and ICU admission has both strength and limitations. While ICU admission is a clinical decision, it is, especially early on in a new disease, sometimes a measure of precaution. This might weaken the association of indicators with clinical outcomes. At the same time, when capacity of ICU beds is exhausted, triage decisions might have been made based on age and co-morbidities to not admit to the ICU, thus strengthening an association of an indicator beyond what would be expected under routine conditions. We also assessed the association with hospitalization and intubation (see Supplement), but here confounding factors seemed to be even more pronounced, and data are further limited. In addition, with improving care and novel therapies certain associations might be less pronounced. We did not observe improved survival of antiviral therapy in the studies included, suggesting that this effect might not yet have occurred in the timeframe of studies included here.

Additional limitations primarily relate to data quality of the included studies. Our quality assessment of studies clearly indicated that substantial bias was present across studies. Primarily the selection bias as suggested for example by the high case fatality rate (e.g. Zhou et al. [11], 28.3%, Chen et al. [115] 11.1%, and Huang et al. [12] 14.6%) is likely to have impacted our results and prospective data collection to confirm findings of these studies is important [116]. In addition, we found a large number of studies (n=21, list available in supplementary file S3) that included laboratory values that were obviously incorrect, which suggests that

despite peer-review in some of them, the rush of publication in this pandemic impacted the quality of reporting [117].

Conclusion

Our data on mortality and ICU admission confirms most of the proposed indicators of clinical outcomes, clarifies the strength of association and highlights additional indicators. In addition, this systematic review highlights the limitations of the studies published and calls for better quality in prospective collections.

Acknowledgements

We thank Genevieve Gore for her help with the search terms. We thank Stephani Schmitz, Sara Kraker, Marlene Ganslmeier and Amelie Muth for their help with the data extraction and Sinan Onogur, Laura Aguilera Saiz, and Bünyamin Pekdemir for their help setting up the data extraction tool.

Funding

SK, AJZ, CG, JG, AS, LMH, GG, AB, JL, MAW, SM, SS, SaK, MG, AM, SO, LAS, BP and CMD declare no conflict of interest.

SM acknowledges support from the National Science Foundation Graduate Research Fellowship Program under Grant No. DGE1745303, National Library Of Medicine of the National Institutes of Health under Award Number T32LM012411, and Fonds de recherche du Québec-Nature et technologies B1X research scholarship.

CMD acknowledges the support of the Heidelberg University Hospital and the German Center of Infectious Disease, where Heidelberg is a core site as part of the tuberculosis focus group.

The work was supported by Heidelberg University Hospital internal funds

Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the funding agencies.

References

1. World Health Organization (WHO). *Coronavirus disease 2019 (COVID-19) Situation Report - 72*. 2020 [27.10.2020]; Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200401-sitrep-72-covid-19.pdf?sfvrsn=3dd8971b_2.
2. Worldometers.info. *COVID-19 Coronavirus Pandemic*. 2020 [02.11.2020]; Available from: <https://www.worldometers.info/coronavirus/>.
3. Zheng, Z., et al., *Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis*. J Infect, 2020. **81**(2): p. e16-e25.
4. Chen, R., et al., *Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China*. Chest, 2020. **158**(1): p. 97-105.
5. Xie, Y., et al., *Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis*. BMC Infect Dis, 2020. **20**(1): p. 640.
6. Li, J., et al., *Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes*. J Med Virol, 2020.
7. Williamson, E.J., et al., *Factors associated with COVID-19-related death using OpenSAFELY*. Nature, 2020. **584**(7821): p. 430-436.
8. Romero Starke, K., et al., *The Age-Related Risk of Severe Outcomes Due to COVID-19 Infection: A Rapid Review, Meta-Analysis, and Meta-Regression*. Int J Environ Res Public Health, 2020. **17**(16).
9. Arentz, M., et al., *Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State*. JAMA, 2020.
10. Tang, J.W., et al., *Comparing hospitalised, community and staff COVID-19 infection rates during the early phase of the evolving COVID-19 epidemic*. J Infect, 2020. **81**(4): p. 647-679.
11. Zhou, F., et al., *Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study*. Lancet, 2020. **395**(10229): p. 1054-1062.
12. Huang, C., et al., *Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China*. Lancet, 2020. **395**(10223): p. 497-506.
13. Wang, D., et al., *Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China*. JAMA, 2020. **323**(11): p. 1061-1069.
14. Fang, L., G. Karakiulakis, and M. Roth, *Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?* The Lancet Respiratory Medicine, 2020. **8**(4): p. e21.
15. Guan, W.-j., et al., *Clinical Characteristics of Coronavirus Disease 2019 in China*. New England Journal of Medicine, 2020. **382**(18): p. 1708-1720.
16. Yang, X., et al., *Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study*. Lancet Respir Med, 2020. **8**(5): p. 475-481.
17. Drager, L.F., et al., *Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic?* Curr Hypertens Rep, 2020. **22**(6): p. 43.
18. Gao, C., et al., *Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study*. Eur Heart J, 2020. **41**(22): p. 2058-2066.
19. Williamson, E.J., et al., *OpenSAFELY: factors associated with COVID-19 death in 17 million patients*. Nature, 2020.
20. Zhao, Q., et al., *The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis*. J Med Virol, 2020.
21. Guo, F.R., *Active smoking is associated with severity of coronavirus disease 2019 (COVID-19): An update of a meta-analysis*. Tob Induc Dis, 2020. **18**: p. 37.
22. Vardavas, C.I. and K. Nikitara, *COVID-19 and smoking: A systematic review of the evidence*. Tobacco Induced Diseases, 2020. **18**(March).
23. World Health Organization (WHO). *Smoking and COVID-19*. 2020 [18.10.2020]; Available from: <https://www.who.int/news-room/commentaries/detail/smoking-and-covid-19>.

24. Herold, T., et al., *Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19*. J Allergy Clin Immunol, 2020. **146**(1): p. 128-136 e4.
25. Lippi, G. and M. Plebani, *Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis*. Clin Chim Acta, 2020. **505**: p. 190-191.
26. Tang, N., et al., *Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia*. J Thromb Haemost, 2020. **18**(4): p. 844-847.
27. Wang, F., et al., *Clinical Characteristics of 28 Patients with Diabetes and Covid-19 in Wuhan, China*. Endocr Pract, 2020. **26**(6): p. 668-674.
28. Cummings, M.J., et al., *Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study*. Lancet, 2020. **395**(10239): p. 1763-1770.
29. Gao, L., et al., *Prognostic value of NT-proBNP in patients with severe COVID-19*. Respir Res, 2020. **21**(1): p. 83.
30. Bauchner, H., R.M. Golub, and J. Zylke, *Editorial Concern-Possible Reporting of the Same Patients With COVID-19 in Different Reports*. JAMA, 2020. **323**(13): p. 1256.
31. Higgins JPT, S.J., Page MJ, Elbers RG, Sterne JAC, *Chapter 8: Assessing risk of bias in a randomized trial*, in *Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020)*, T.J. Higgins JPT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, Editor. 2020.
32. McGrath, S., et al., *Meta-analysis of the difference of medians*. Biom J, 2020. **62**(1): p. 69-98.
33. McGrath, S.S., Russell; Benedett, Andrea *metamedian: Meta-Analysis of Medians*. R package version 0.1.5. 2020; Available from: <https://cran.r-project.org/web/packages/metamedian/metamedian.pdf>.
34. Urra, J.M., et al., *Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients*. Clin Immunol, 2020. **217**: p. 108486.
35. Martin-Moro, F., et al., *Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies*. Br J Haematol, 2020. **190**(1): p. e16-e20.
36. Sun, S., et al., *Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China*. Clin Chim Acta, 2020. **507**: p. 174-180.
37. Hong, K.S., et al., *Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study*. Yonsei Med J, 2020. **61**(5): p. 431-437.
38. Lei, S., et al., *Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection*. EClinicalMedicine, 2020. **21**: p. 100331.
39. Cholankeril, G., et al., *Association of Digestive Symptoms and Hospitalization in Patients With SARS-CoV-2 Infection*. Am J Gastroenterol, 2020. **115**(7): p. 1129-1132.
40. Antinori, S., et al., *Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status*. Pharmacol Res, 2020. **158**: p. 104899.
41. Cao, M., et al., *Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China*. medRxiv, 2020.
42. Smadja, D.M., et al., *Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients*. Angiogenesis, 2020. **23**(4): p. 611-620.
43. Ferguson, J., et al., *Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions, Northern California, USA, March-April 2020*. Emerg Infect Dis, 2020. **26**(8): p. 1679-1685.
44. Israelsen, S.B., et al., *Characteristics of patients with COVID-19 pneumonia at Hvidovre Hospital, March-April 2020*. Dan Med J, 2020. **67**(6).
45. Yang, L., et al., *Epidemiological and clinical features of 200 hospitalized patients with corona virus disease 2019 outside Wuhan, China: A descriptive study*. J Clin Virol, 2020. **129**: p. 104475.

46. Criel, M., et al., *Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?* Eur Respir J, 2020. **56**(1).
47. Rieg, S., et al., *[COVID-19-Response - Strategies of the Task-Force Coronavirus and experiences upon implementation in the management of 115 cases at the University Medical Center Freiburg]*. Dtsch Med Wochenschr, 2020. **145**(10): p. 657-664.
48. Zhang, G., et al., *Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China*. J Clin Virol, 2020. **127**: p. 104364.
49. Memtsoudis, S.G., et al., *Obesity as a risk factor for poor outcome in COVID-19-induced lung injury: the potential role of undiagnosed obstructive sleep apnoea*. Br J Anaesth, 2020. **125**(2): p. e262-e263.
50. Lodigiani, C., et al., *Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy*. Thromb Res, 2020. **191**: p. 9-14.
51. Middeldorp, S., et al., *Incidence of venous thromboembolism in hospitalized patients with COVID-19*. J Thromb Haemost, 2020. **18**(8): p. 1995-2002.
52. Myers, L.C., et al., *Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California*. JAMA, 2020. **323**(21): p. 2195-2198.
53. Rentsch, C.T., et al., *Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years*. medRxiv, 2020.
54. Argenziano, M.G., et al., *Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series*. BMJ, 2020. **369**: p. m1996.
55. Petrilli, C.M., et al., *Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study*. BMJ, 2020. **369**: p. m1966.
56. Li, K., et al., *Radiographic Findings and other Predictors in Adults with Covid-19*. medRxiv, 2020: p. 2020.03.23.20041673.
57. Zhang, F., et al., *Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study*. medRxiv, 2020: p. 2020.03.21.20040121.
58. Fu, L., et al., *Influence factors of death risk among COVID-19 patients in Wuhan, China: a hospital-based case-cohort study*. medRxiv, 2020: p. 2020.03.13.20035329.
59. Wang, Z., et al., *Elevated serum IgM levels indicate poor outcome in patients with coronavirus disease 2019 pneumonia: A retrospective case-control study*. medRxiv, 2020: p. 2020.03.22.20041285.
60. Xie, J., et al., *Development and external validation of a prognostic multivariable model on admission for hospitalized patients with COVID-19*. medRxiv, 2020: p. 2020.03.28.20045997.
61. Russo, V., et al., *Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study*. Pharmacol Res, 2020. **159**: p. 104965.
62. Shi, Q., et al., *Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study*. Diabetes Care, 2020. **43**(7): p. 1382-1391.
63. Raoufi, M., et al., *Correlation between Chest Computed Tomography Scan Findings and Mortality of COVID-19 Cases; a Cross sectional Study*. Arch Acad Emerg Med, 2020. **8**(1): p. e57.
64. Luo, X., et al., *Prognostic value of C-reactive protein in patients with COVID-19*. Clin Infect Dis, 2020.
65. Tang, N., et al., *Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy*. J Thromb Haemost, 2020. **18**(5): p. 1094-1099.
66. Wang, L., et al., *Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up*. J Infect, 2020. **80**(6): p. 639-645.
67. Conversano, A., et al., *Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study*. Hypertension, 2020. **76**(2): p. e10-e12.

68. Cao, J., et al., *Clinical Features and Short-term Outcomes of 102 Patients with Coronavirus Disease 2019 in Wuhan, China*. Clin Infect Dis, 2020. **71**(15): p. 748-755.
69. Yang, X., et al., *Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019-Induced Acute Respiratory Distress Syndrome: A Multicenter Descriptive Study*. Crit Care Med, 2020. **48**(9): p. 1289-1295.
70. Giacomelli, A., et al., *30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study*. Pharmacol Res, 2020. **158**: p. 104931.
71. Goicoechea, M., et al., *COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain*. Kidney Int, 2020. **98**(1): p. 27-34.
72. Borghesi, A., et al., *Chest X-ray severity index as a predictor of in-hospital mortality in coronavirus disease 2019: A study of 302 patients from Italy*. Int J Infect Dis, 2020. **96**: p. 291-293.
73. Zhang, F., et al., *Obesity predisposes to the risk of higher mortality in young COVID-19 patients*. J Med Virol, 2020.
74. Wu, C., et al., *Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China*. JAMA Intern Med, 2020. **180**(7): p. 934-943.
75. Huang, J., et al., *Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity*. J Med Virol, 2020.
76. Valeri, A.M., et al., *Presentation and Outcomes of Patients with ESKD and COVID-19*. J Am Soc Nephrol, 2020. **31**(7): p. 1409-1415.
77. Zhang, J., et al., *The clinical data from 19 critically ill patients with coronavirus disease 2019: a single-centered, retrospective, observational study*. Z Gesundh Wiss, 2020: p. 1-4.
78. Hu, H., N. Yao, and Y. Qiu, *Comparing Rapid Scoring Systems in Mortality Prediction of Critically Ill Patients With Novel Coronavirus Disease*. Acad Emerg Med, 2020. **27**(6): p. 461-468.
79. Lee, L.Y., et al., *COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study*. Lancet, 2020. **395**(10241): p. 1919-1926.
80. Yuan, M., et al., *Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China*. PLoS One, 2020. **15**(3): p. e0230548.
81. Chen, T., et al., *Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study*. BMJ, 2020. **368**: p. m1091.
82. Tu, W.J., et al., *Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan*. Intensive Care Med, 2020. **46**(6): p. 1117-1120.
83. Auld, S.C., et al., *ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 2019*. Crit Care Med, 2020. **48**(9): p. e799-e804.
84. Sun, H., et al., *Risk Factors for Mortality in 244 Older Adults With COVID-19 in Wuhan, China: A Retrospective Study*. J Am Geriatr Soc, 2020. **68**(6): p. E19-E23.
85. Yang, K., et al., *Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study*. Lancet Oncol, 2020. **21**(7): p. 904-913.
86. Chen, R., et al., *Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China*. J Allergy Clin Immunol, 2020. **146**(1): p. 89-100.
87. Zhao, X., et al., *Early decrease in blood platelet count is associated with poor prognosis in COVID-19 patients-indications for predictive, preventive, and personalized medical approach*. EPMA J, 2020: p. 1-7.
88. Deng, G., et al., *Clinical determinants for fatality of 44,672 patients with COVID-19*. Crit Care, 2020. **24**(1): p. 179.
89. Zou, X., et al., *Acute Physiology and Chronic Health Evaluation II Score as a Predictor of Hospital Mortality in Patients of Coronavirus Disease 2019*. Crit Care Med, 2020.
90. Li, L., et al., *Association of clinical and radiographic findings with the outcomes of 93 patients with COVID-19 in Wuhan, China*. Theranostics, 2020. **10**(14): p. 6113-6121.
91. Fan, H., et al., *Cardiac injuries in patients with coronavirus disease 2019: Not to be ignored*. Int J Infect Dis, 2020. **96**: p. 294-297.

92. Crespo, M., et al., *COVID-19 in elderly kidney transplant recipients*. Am J Transplant, 2020. **20**(10): p. 2883-2889.
93. Nowak, B., et al., *Clinical characteristics and short-term outcomes of patients with coronavirus disease 2019: a retrospective single-center experience of a designated hospital in Poland*. Pol Arch Intern Med, 2020. **130**(5): p. 407-411.
94. Klang, E., et al., *Severe Obesity as an Independent Risk Factor for COVID-19 Mortality in Hospitalized Patients Younger than 50*. Obesity (Silver Spring), 2020. **28**(9): p. 1595-1599.
95. Pan, F., et al., *Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study*. Int J Med Sci, 2020. **17**(9): p. 1281-1292.
96. Yan, X., et al., *Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study*. J Med Virol, 2020.
97. Xu, P.P., et al., *Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study*. Theranostics, 2020. **10**(14): p. 6372-6383.
98. Moon, A.M., et al., *High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry*. J Hepatol, 2020. **73**(3): p. 705-708.
99. Wang, K., et al., *Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China*. Clin Infect Dis, 2020.
100. Paranjpe, I., et al., *Clinical Characteristics of Hospitalized Covid-19 Patients in New York City*. medRxiv, 2020.
101. Yu, C., et al., *Clinical Characteristics, Associated Factors, and Predicting COVID-19 Mortality Risk: A Retrospective Study in Wuhan, China*. Am J Prev Med, 2020. **59**(2): p. 168-175.
102. Tomlins, J., et al., *Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort*. J Infect, 2020. **81**(2): p. e59-e61.
103. Javanian, M., et al., *Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study*. Rom J Intern Med, 2020. **58**(3): p. 161-167.
104. Qi, X., et al., *Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study*. Gut, 2020.
105. Xu, B., et al., *Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China*. J Infect, 2020. **81**(1): p. e51-e60.
106. Deng, Y., et al., *Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study*. Chin Med J (Engl), 2020. **133**(11): p. 1261-1267.
107. Wang, D., et al., *Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China*. Crit Care, 2020. **24**(1): p. 188.
108. Du, R.H., et al., *Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study*. Eur Respir J, 2020. **55**(5).
109. Atkins, J.L., et al., *Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort*. J Gerontol A Biol Sci Med Sci, 2020. **75**(11): p. 2224-2230.
110. Mao, L., et al., *Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China*. JAMA Neurol, 2020. **77**(6): p. 683-690.
111. Pleasure, S.J., A.J. Green, and S.A. Josephson, *The Spectrum of Neurologic Disease in the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic Infection: Neurologists Move to the Frontlines*. JAMA Neurol, 2020. **77**(6): p. 679-680.
112. Schultze, A., et al., *Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform*. Lancet Respir Med, 2020.
113. Tan, L., et al., *Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study*. Signal Transduct Target Ther, 2020. **5**(1): p. 33.
114. Huang, I. and R. Pranata, *Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis*. J Intensive Care, 2020. **8**: p. 36.

115. Chen, N., et al., *Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study*. Lancet, 2020. **395**(10223): p. 507-513.
116. Jakob, C.E.M., et al., *First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)"*. Infection, 2020.
117. Bramstedt, K.A., *The carnage of substandard research during the COVID-19 pandemic: a call for quality*. J Med Ethics, 2020.

Table 1 - Summary of the meta-analysis results for continuous indicators comparing those who were admitted to the ICU and those who were not

Indicator	N. Studies	Pooled DoM [95% CI]	I ²
Demographics			
Age (years)	22	4.63 [1.43, 7.82]	89.89
Clinical Values			
Respiratory Rate (per min)	5	3.15 [0.11, 6.19]	79.27
Laboratory Values			
Hemoglobin (g/L)	7	-5.97 [-11.78, -0.16]	56.12
Leukocyte (10 ⁹ /L)	15	1.2 [0.54, 1.85]	62.23
Lymphocyte (10 ⁹ /L)	19	-0.26 [-0.34, -0.17]	75.34
Neutrophil (10 ⁹ /L)	14	2.67 [1.43, 3.91]	89.14
Platelets (10 ⁹ /L)	17	-10.4 [-20.83, 0.04]	32.66
APTT (sec)	7	0.38 [-1.2, 1.95]	49.45
D-Dimer* (mg/L)	14	0.30 [-0.20, 0.81]	83.97
Prothrombin (sec)	7	0.48 [0.2, 0.76]	0.00
ALAT (U/L)	15	4.37 [2.11, 6.64]	16.17
Albumin (g/L)	5	-6.05 [-8.75, -3.35]	79.38
ASAT (U/L)	13	11.77 [7.24, 16.3]	64.91
LDH (U/L)	12	140.4 [81.04, 199.76]	86.32
BUN (mmol/L)	7	1.9 [1.34, 2.45]	0.00
Creatinine (μmol/L)	16	9.41 [5.18, 13.63]	40.23
CRP* (mg/L)	10	56.41 [39.8, 73.02]	76.56
PCT (ng/mL)	6	0.08 [-0.01, 0.16]	88.76
CK (U/L)	9	33.57 [1.76, 65.38]	55.08
CK-MB (U/L)	4	2.47 [0.67, 4.26]	0.00

Tnl* (pg/mL)	6	19.27 [-4.13, 42.68]	96.82
--------------	---	----------------------	-------

*Caption: *Indicates that the DL approach was used to estimate between-study heterogeneity. APTT = activated partial thrombin time; ALAT = Alanine transaminase; ASAT = Aspartate transaminase; LDH = Lactate dehydrogenase; BUN = Blood urea nitrogen; CRP = C-reactive protein; PCT = Procalcitonin CK = creatine kinase; CK-MB = creatine kinase – myocardial band; Tnl = Troponin I*

Table 2 - Summary of the meta-analysis results for continuous indicators comparing those who died and those who survived

Indicator	N. Studies	Pooled DoM [95% CI]	I ²
Demographics			
Age (years)	52	13.15 [11.37, 14.94]	86.74
Clinical Values			
SpO2 - without O2 (%)	15	-6.33 [-8.14, -4.52]	81.77
Respiratory Rate (per min)	15	3.41 [2.26, 4.55]	62.32
Laboratory Values			
Hemoglobin (g/L)	18	-2.66 [-5.12, -0.2]	43.36
Leukocyte (10 ⁹ /L)	37	2.79 [2.23, 3.35]	70.35
Lymphocyte (10 ⁹ /L)	38	-0.34 [-0.39, -0.29]	70.03
Neutrophil (10 ⁹ /L)	25	3.26 [2.56, 3.95]	82.2
Platelets (10 ⁹ /L)	30	-31.94 [-41.11, -22.77]	58.13
APTT (sec)	16	0.59 [-0.51, 1.69]	61.88
D-Dimer (mg/L)*	30	1.29 [0.90, 1.69]	81.53
Fibrinogen (g/L)	7	0.01 [-0.12, 0.15]	0.00
INR	7	0.06 [0.01, 0.12]	63.31
Prothrombin (sec)	25	0.91 [0.67, 1.14]	54.65
ALAT (U/L)	34	4.43 [2.41, 6.46]	26.64
Albumin (g/L)	21	-4.64 [-5.83, -3.45]	85.16
ASAT (U/L)	27	13.35 [10.54, 16.15]	42.83
LDH (U/L)	23	189.49 [155, 223.98]	75.03
BUN (mmol/L)	17	2.77 [2.07, 3.46]	66.77
Creatinine (μmol/L)	29	15.3 [10.3, 20.29]	61.63
CRP (mg/L)*	34	69.1 [50.43, 87.77]	95.99
IL-6 (pg/mL)	11	31.19 [11.96, 50.41]	99.75

PCT (ng/mL)	18	0.16 [0.1, 0.22]	68.09
BNP (pg/mL)	7	405.26 [116.51, 694.02]	95.81
CK (U/L)	18	64.09 [29.04, 99.13]	81.47
CK-MB (U/L)	9	3.66 [1.19, 6.14]	67.12
TnI (pg/mL)*	13	21.88 [9.78, 33.99]	75.17

*Caption: *Indicates that the DL approach was used to estimate between-study heterogeneity. SpO2 = Oxygen saturation; APTT = activated partial thrombin time; INR = Internationalized normalized ratio; ALAT = Alanine transaminase; ASAT = Aspartate transaminase; LDH = Lactate dehydrogenase; BUN = Blood urea nitrogen; CRP = C-reactive protein; IL-6 = Interleukin-6; BNP = brain natriuretic peptide; PCT = Procalcitonin CK = creatine kinase; CK-MB = creatine kinase – myocardial band; TnI = Troponin I*

Figures

Figure 1 PRISMA Flow Diagram

Figure 2 Risk of bias assessment

Figure 3 Pooled risk ratios among (A) ICU vs. non ICU groups and (B) mortality vs. survived groups

Figure 4 Pooled median estimates of selected indicators along with their normal laboratory ranges among patients who died, patients who survived, ICU-admitted patients, and non-ICU admitted patients

Figure 1 - PRISMA Flow Diagram

PRISMA 2009 Flow Diagram

Figure 2 - Risk of bias assessment

Figure 3a - Pooled odds ratios among ICU vs. non ICU groups

Caption: COPD = chronic obstructive pulmonary disease, ART = anti-retroviral therapy, NIV = non-invasive ventilation, OR = odds ratio, CI = Confidence Interval

Figure 3b - Pooled odds ratios among mortality vs. survival groups

Caption: COPD = chronic obstructive pulmonary disease, ART = anti-retroviral therapy, NIV = non-invasive ventilation, ECMO = extra corporal membrane oxygenation, OR = odds ratio, CI = Confidence Interval

Figure 4 - Pooled median estimates of selected indicators along with their normal laboratory ranges among patients who died, patients who survived, ICU-admitted patients, and non-ICU admitted patients

Caption: Normal range (grey) was used as stated in included publications. If different normal ranges are reported in included publications, we used the lowest and highest values. Leukocytes and Lymphocytes upper range of the normal range is $11.0 \times 10^9/L$ and $4.0 \times 10^9/L$, respectively. CRP = C-reactive protein; LDH = Lactate dehydrogenase;